OMICS Journals are welcoming Submissions

OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS International follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website: http://omicsonline.org/Submitmanuscript.php





Benyi Li, Ph.D

Associate Professor
Department of Urology
University of Kansas
USA

Tel: 913-588-4775

Fax: 913-588-6257

Editor of

MEDICAL & SURGICAL UROLOGY

BIOGRAPHY

Dr Benyi Li received his PhD in Fukui University of Japan in Dec 1997. Currently, he is an Associate Professor and Director for Basic Research of the Department of Urology in the University of Kansas Medical center. He also has an administrative responsibility as the Associate Director of Biomedical Research Training Program at the University. He is serving as an editorial member of the Journal of Contemporary Urological Oncology. He has authored more than 80 research articles and book chapters. He is a member of AACR, AUA, EUA and SBUR.

RESEARCH INTEREST



Prostate cancer, androgen signaling, PI3K pathway and histone modification, GSK-3 modulation of cell death, nano-medicine, experimental cancer therapeutics.

wek Photo - cen*

MY PUBLICATIONS!!!

Tang Y, Chen R, Huang Y, Li G, Huang Y, Chen J, Duan L, Zhu BT, Thrasher JB, Zhang X, Li B. Natural compound Alternol induces oxidative stress-dependent apoptotic cell death preferentially in prostate cancer cells. Mol Cancer Ther. 2014 Mar 31. [Epub ahead of print]

Liu WJ, Luo MN, Tan J, Chen W, Huang LZ, Yang C, Pan Q, Li B, Liu HF. Autophagy activation reduces renal tubular injury induced by urinary proteins. Autophagy. 2013 Nov 26;10(2).

Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, Liu J, Tawfik O, Brantley Thrasher J, Li B. Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol. 2013 Sep 17. pii: S1078-1439(13)00243-3.

Yang J, Xie SX, Huang Y, Ling M, Liu J, Ran Y, Wang Y, Thrasher JB, Berkland C, Li B. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor 1 silencing constructs eradicate xenograft tumors in mice. Nanomedicine (Lond). 2012 Sep; 7(9):1297-309.

Zhao Y, Duan S, Zeng X, Liu C, Davies NM, Li B, Forrest ML. Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm. 2012 Jun 4;9(6):1705-16. Epub 2012 May 1.

Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. The Prostate. 2012 Sep 15; 72(13):1423-30.

Cai Z, Li B, Li K, Zhao B. Down-Regulation of Amyloid-β Through AMPK Activation by Inhibitors of GSK-3β in SH-SY5Y and SH-SY5Y-AβPP695 Cells. J Alzheimers Dis. 2012; 29(1):89-98.

Chen P, Yu J, Chalmers B, Drisko J, Yang J, Li B, Chen Q. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs. 2011 23(4):437-44...

Tai W, Shukla RS, Qin B, Li B, Cheng K. Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics, 2011 Jun 6;8(3):901-12.






NANOMEDICINE

After Nanotechnology, we moved on to the different field with this e.g. nanobiotechnology, nanoanatomy, nanophysiology etc. are some of the fields invented one by one. In this line, with the era we have came across a field which we can termed as nanomedicine. Nanomedicine is a medical field of nanotechnology. It ranges from the different applications of pharmacy itself like nanoparticles, nanomaterials etc. this may give to other nanotechnology world for different field section in the upcoming future.

Perhaps this may include the commercial applications from the pharmaceutical field which includes advanced drug delivery systems, compartment modeling, new therapies, different ways of medications etc. are involved in the new field termed as NANO-MEDICINE

WHERE NANOMEDICINE LIES???


It is such a big field that up till now it makes the sale around \$6.8 billion in 2004, and with over 200 companies and 38 products worldwide, a minimum of \$3.8 billion in nanotechnology R&D is being invested every year. In April 2006, the journal Nature Materials estimated that 130 nanotech-based drugs and delivery systems were being developed world wide. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.




Features of Nanomedicine

Beyond every applications and uses of nanomedicine it still have some special features which are as follows:

- ✓ As nanomedicine use nano-tools to treat the part of body which is 1000 times smaller than a cell which helps the medicine in increasing penetrating power inside the cell.
- ✓ Can reach on the target cell.
- ✓ Can combine with the molecular biosensors only.





THIS COULD BE THE FUTURE!!!



Approved By Benyi Li

E-signature: bli@kumc.edu



http://omicsonline.org/membership.php

